ClinicalTrials.gg
RecruitingNCT07845552Updated Oct 28, 2026

Oral Food Challenge After One to Two Doses of Omalizumab Treatment for Food Allergy

A Phase 4 interventional study of Omalizumab in Food Allergy, sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Johns Hopkins University · Phase 4, Interventional, and Treatment

Updated Oct 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
1 Year to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing omalizumab in Food Hypersensitivity — 4 open to participants now, 4 under way, none of them phase 3. Omalizumab · Food Hypersensitivity.

Planned enrollment
10th of 12
20 · median 34
Started
2026
the only one that year
Phase 4
5 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
3 of 12
Johns Hopkins University

Among the 12 studies testing omalizumab in Food Hypersensitivity, this one is the 10th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 4, and was the 12th registered.

Food Hypersensitivity

378 studies on the registry are indexed under Food Hypersensitivity; 92 are open to participants now.

Browse Food Hypersensitivity studies →

Open to participants now

4 of the 12 studies testing omalizumab in Food Hypersensitivity are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About omalizumab

Omalizumab: first FDA approval 2003 (XOLAIR), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 54 Food Hypersensitivity studies recruiting now, 8 (15%) set no upper age limit and 42 (78%) stop at 75 or younger; 46 take children under 18; 17 take healthy volunteers.

This study: 1 Year to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing omalizumab in Food Hypersensitivity, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how quickly omalizumab begins to work in people with food allergy. The main question it aims to answer is:

  • Does omalizumab begin to work as early as 2 to 4 weeks after after starting treatment in people with food allergy?

Researchers will compare each participant's food challenge results at baseline before starting omalizumab, 2 to 4 weeks after starting omalizumab, and 4 to 6 months after starting omalizumab treatment.

Participants will:

  • Have a baseline food challenge before starting omalizumab.
  • Start omalizumab treatment as prescribed by the participant's doctor as part of regular clinical care.
  • Have food challenges 2 to 4 weeks after starting omalizumab and again 4 to 6 months after starting omalizumab.
  • Have skin prick testing and blood tests at study visits.
03

Conditions studied

  • Food Allergy

Browse trials for

Keywords

  • food allergy
  • omalizumab
  • oral food challenge
04

Who can participate

Ages eligible
1 Year to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 1 to 30 years.
  • Patients with diagnosed food allergy to at least one of the following foods (milk, egg, wheat, peanut, cashew, or walnut) who were prescribed omalizumab for food allergy in the clinical setting at the Johns Hopkins pediatric or adult allergy clinic.
  • Positive food-specific IgE (≥2.0 kUA/L) to the relevant food OR a positive skin-prick test with a wheal ≥4 mm larger than the saline control.
  • Positive open oral food challenge at baseline screening evaluation to the relevant food with dose-limiting symptoms at a single dose of ≤1000 mg (cumulative dose of ≤2043 mg) prior to starting omalizumab (using incremental doses of 3, 10, 30, 100, 300, 600, 1000 mg).
  • Prior authorization from the patient's insurance provider for clinical use of omalizumab.

Exclusion criteria

Exclusion Criteria:

  • laboratory abnormalities in the past 6 months.
  • Sensitivity or suspected/known allergy to any ingredients (including ) of omalizumab
  • Poorly controlled or severe asthma/wheezing at screening
  • History of severe anaphylaxis to the participant-specific food that will be used in this study, defined as neurological compromise or requiring intubation.
  • Currently receiving oral, intramuscular (IM), or intravenous (IV) , tricyclic antidepressants, or β-blockers.
  • Past or current history of cancer, or currently being investigated for possible cancer.
  • Past or current history of any food immunotherapy, such as oral immunotherapy (OIT), sublingual immunotherapy (SLIT), epicutaneous immunotherapy (EPIT) within 6 months of screening.
  • Treatment with monoclonal antibody therapy, such as omalizumab, dupilumab, benralizumab, mepolizumab, reslizumab, tezepelumab, or other immunomodulatory therapy within 6 months of screening.
  • Inability to discontinue antihistamines for minimum required for skin-prick test or oral food challenge.
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • Evidence of clinically significant chronic disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    omalizumab

    Omalizumab is approved by the FDA for the treatment of food allergy in patients aged 1 year and older. Omalizumab is administered as a subcutaneous injection at doses ranging from 75 mg to 600 mg every 2 or 4 weeks. Omalizumab treatment is not provided as part of this study. Participants will receive omalizumab treatment as part of their routine care for food allergy as prescribed by their doctor in the clinical setting.

    Drug: Omalizumab

Interventions

  • Prior to starting omalizumab, participants will undergo a baseline oral food challenge. Participants will then initiate omalizumab treatment as prescribed by their doctor as part of routine clinical care. After 2 to 4 weeks of treatment (following one to two doses of omalizumab), participants will undergo a first post-treatment oral food challenge to assess treatment response. After 4 to 6 months of omalizumab treatment, participants will undergo a second post-treatment oral food challenge. The study will conclude following the second post-treatment oral food challenge.

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving pre-specified thresholds without dose-limiting symptoms during first post-treatment oral food challenge.

    The pre-specified thresholds for response is defined as the ability to consume at least two more incremental doses of food protein during post-treatment oral food challenge (using incremental doses of 3, 10, 30, 100, 300, 600, 1000, 2000, 2000, and 2000 mg), than during the baseline oral food challenge. First post-treatment oral food challenge conducted between ≥14 and ≤35 days after starting omalizumab (after one or two doses of omalizumab depending on whether the participant is receiving omalizumab every 2 or 4 weeks).

    Time frame: Between ≥14 and ≤35 days after starting omalizumab

Secondary outcomes

  1. The absolute change in oral food challenge threshold between baseline and the first post-treatment oral food challenge.

    Baseline oral food challenge conducted prior to starting omalizumab. First post-treatment oral food challenge conducted at ≥14 and ≤35 days after starting of omalizumab.

    Time frame: Baseline, between ≥14 and ≤35 days after starting omalizumab

  2. The absolute change in oral food challenge threshold between the first and second post-treatment oral food challenges.

    First post-treatment oral food challenge conducted at ≥14 and ≤35 days after starting of omalizumab. Second post-treatment oral food challenge conducted between 4 to 6 months after starting omalizumab.

    Time frame: between ≥14 and ≤35 days after starting omalizumab, 4-6 months after starting omalizumab

Other outcomes

  1. Correlation between oral food challenge threshold and biomarkers including skin prick testing, allergen-specific IgE, total IgE, and free total IgE.

    Oral food challenge threshold measures the amount of food protein (mg) consumed without dose-limiting symptoms. Biomarkers include skin prick test measured by wheal diameter (mm), allergen-specific IgE concentration (kUA/L), total IgE concentration (IU/mL), and free total IgE concentration (IU/mL).

    Time frame: At baseline, between ≥14 and ≤35 days starting omalizumab, and 4 to 6 months after starting omalizumab

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There are no plans to share individual participant data.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartActual
Oct 19, 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
Johns Hopkins Hospital is now Recruiting
Oct 28, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • Editedother outcomeAssociationCorrelation between oral food challenge outcomesthreshold and biomarkers including skin prick testing, allergen-specific IgE, total IgE, and free total IgE.Time frame: At baseline, between ≥14 and ≤35 days starting omalizumab, and 4 to 6 months after starting omalizumab
Oct 14, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 3 updates
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    Johns Hopkins Hospital is now Recruiting
    + 1 other change: date precision
  2. Oct 14, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • Editedother outcomeAssociationCorrelation between oral food challenge outcomesthreshold and biomarkers including skin prick testing, allergen-specific IgE, total IgE, and free total IgE.Time frame: At baseline, between ≥14 and ≤35 days starting omalizumab, and 4 to 6 months after starting omalizumab
    + 1 other change: verification date
  3. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07845552
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 19, 2026
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Hao Tseng, MD
Contact
htseng9@jh.edu
410-955-5883
Robert Wood, MD
Contact
rwood@jhmi.edu
410-955-5883
Robert Wood, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omalizumab

Start the discussion